ClinicalTrials.gg
Status unknownNCT02713451LOCO2Updated Jul 12, 2019

Liberal Oxygenation Versus Conservative Oxygenation in ARDS

A Phase 3 interventional study of Modulation of Inspired Fraction of Oxygen (FiO2) in Acute Respiratory Distress Syndrome and Intensive Care, sponsored by Centre Hospitalier Universitaire de Besancon. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-12.

Sponsored by Centre Hospitalier Universitaire de Besancon · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2018), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

No clear recommendation exists for the level of oxygenation of intensive care patients. In Acute Respiratory Distress Syndrome (ARDS), pulsed oxymetry (SpO2) have to be kept between 88 and 95 percent and oxygen alveolar pressure between 55 and 80 mmHg (PaO2). These recommendations are common but do not lie on high scientific knowledge and level of proof. In the major studies of these fifteen last years that changed ARDS management, PaO2 was kept around 85 and 90 mmHg despite current recommendations of 55 to 80 mmHg of PaO2.

Many recent review and cohort studies pointed the risk of excessive oxygenation especially following cardiac arrest, stroke or traumatic brain injury. However, these data come in majority from cohort or database study without strong definition of hyperoxia. Data coming from prospective studies are scarce and tend to show better outcome of patients with lower objectives of oxygenation in ICU.

High oxygen (O2) level may be deleterious especially on inflammatory lungs. It could enhance injuries due to mechanical ventilation. O2 could be responsable of " hyperoxia induced lung injury ".

The investigators showed in a precedent study that comparing a restrictive oxygenation versus a liberal oxygenation was feasable and do not expose patients to major adverse events. More, mortality at 60 days has tendency to be lower. The investigators therefore ask if a lower objectives of PaO2 in comparison with the level usually seen in last studies on ARDS could improve ARDS patients outcome.

The aim of this study is to show that a restrictive oxygenation in comparison with a liberal oxygenation strategy in patients with ARDS would lower mortality at 28 days.

Read the detailed description

It is a prospective, comparative, randomized, multicentric, french, open study. Patients with ARDS will be enrolled and will be allocated to Liberal Oxygenation arm (LO) or to Conservative Oxygenation arm (CO) during the invasive mechanical ventilation procedure in ICU.

In LO arm, objective of PaO2 is 90 to 105 mmHg. In CO arm, objective of PaO2 is 55 to 70 mmHg.

02

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Intensive Care

Keywords

  • Oxygen
03

In context

Respiratory Distress Syndrome

1,619 studies on the registry are indexed under Respiratory Distress Syndrome; 319 are open to participants now.

This study's enrollment of 206 is above the median of 60 across 973 interventional studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Centre Hospitalier Universitaire de Besancon is the lead sponsor of 449 studies on the registry; 98 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major patients with mechanical ventilation
  • ARDS according to Berlin definition:Hypoxemia defined with PaO2 FiO2 ratio less or equal to 300 mmHg with Positive End Expiratory Pressure higher or equal to 5 cmH20, Less than seven days between a known clinical insult or new or worsening of respiratory symptoms, Bilateral opacities on chest Imaging not fully explained by effusions, lobar or lung collapse, or nodules, Respiratory failure not fully explained by cardiac failure or fluid overload
  • Less than twelve hours following initiation of mechanical ventilation.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Patient less than 18 years old
  • Sickle cell disease
  • Patient deprived of freedom, Under a legal protective measure
  • Cardiac arrest as the reason for ICU hospitalisation
  • Traumatic brain injury as the reason for ICU hospitalisation
  • Hemoptysis with embolization or surgery
  • Extracorporeal life support or Extracorporeal Membrane Oxygenation before randomization
  • Chronic Obstructive Pulmonary Disease with oxygen or non invasive ventilation at home (obstructive sleep apnoea syndrome is not an exclusion criteria)
  • Patient with very high risk of death with IGS II (Simplified Severity Index II) than 90
  • Indication of hyperbaric oxygenation : carbon monoxide intoxication, gas embolism, necrotizing fasciitis
  • Cyanide intoxication, methemoglobinemia
  • Untreated pneumothorax
  • Lymphangitis carcinomatosa
  • Eosinophilic pneumonia
  • Intensive care management for organ donation
  • Participation in another interventional study with mortality as a major outcome to avoid confounding factor
  • Patient not affiliated to social security
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Active comparator
    Liberal Oxygenation (LO) group

    A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.

    Drug: Modulation of Inspired Fraction of Oxygen (FiO2)

  • Experimental
    Conservative Oxygenation (CO) group

    A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.

    Drug: Modulation of Inspired Fraction of Oxygen (FiO2)

Interventions

  • DrugModulation of Inspired Fraction of Oxygen (FiO2)

    In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG). This management of FiO2 will be done until extubation of the patient.

06

What researchers measure

Primary outcomes

  1. Death

    Time frame: Day 28

Secondary outcomes

  1. Death

    Time frame: Day 90

  2. Days free of mechanical ventilation in ICU

    Time frame: Day 28

  3. Sequential Organ Failure Assessment (SOFA) Score

    Sepsis-related Organ Failure Score

    Time frame: Day 0, 3 and 7

  4. Score of morbidity

    This score is based on three points: need for mechanical ventilation, need for Morbidity are renal replacement therapy, need of catecholamine or need for ventilation

    Time frame: Day 28

  5. Ventilator associated pneumonia

    Time frame: Day 28

  6. Septicemia

    Time frame: Day 28

  7. Antibiotic consumption

    Number of days exposed to antibiotics divided by the number of days spent in ICU

    Time frame: Day 28

  8. Cardiovascular complications

    New onset of rhythm disorders, cardiac ischemia and dose of catecholamin at 28 and 90 days

    Time frame: Day 28 and day 90

  9. Neurological evolution

    Neurological evolution measured with daily Richmond Agitation Sedation Scale score, seizures, new stroke, daily sedation doses, neuroleptic administration

    Time frame: Day 28

  10. Respiratory autonomy

    Need for oxygen or mechanical ventilation support

    Time frame: Day 28 and 90

07

Study locations

1 site
  • BARROT Loïc
    Besançon, France
08

References and documents

Publications

  • Panwar R, Hardie M, Bellomo R, Barrot L, Eastwood GM, Young PJ, Capellier G, Harrigan PW, Bailey M; CLOSE Study Investigators; ANZICS Clinical Trials Group. Conservative versus Liberal Oxygenation Targets for Mechanically Ventilated Patients. A Pilot Multicenter Randomized Controlled Trial. Am J Respir Crit Care Med. 2016 Jan 1;193(1):43-51. doi: 10.1164/rccm.201505-1019OC. PubMed 26334785 ↗
  • Barrot L, Asfar P, Mauny F, Winiszewski H, Montini F, Badie J, Quenot JP, Pili-Floury S, Bouhemad B, Louis G, Souweine B, Collange O, Pottecher J, Levy B, Puyraveau M, Vettoretti L, Constantin JM, Capellier G; LOCO2 Investigators and REVA Research Network. Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome. N Engl J Med. 2020 Mar 12;382(11):999-1008. doi: 10.1056/NEJMoa1916431. PubMed 32160661 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02713451
Responsible party
Sponsor
First posted
Mar 18, 2016
Start date
Jun 2016
Primary completion
May 31, 2019
Completion
Sep 28, 2019 (estimated)
Last update
Jul 12, 2019

Study contacts

Loïc Barrot, MD
principal investigator · BESANCON

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion